Articles
The US Food and Drug Administration this week approved denosumab (XGEVA, Amgen) for prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors. Also this week, approval was granted for eribulin mesylate injection (Halaven, Eisai) for treatment of metastatic breast cancer.
Denosumab
Read More ›Treating patients with advanced hepatocellular carcinoma (HCC) with a combination of doxorubicin and sorafenib may increase median time to progression, overall survival, and progression-free survival compared with doxorubicin alone, a new study suggests.
A multidisciplinary clinic approach is the key to successful treatment of aggressive, locally advanced prostate cancer, according to researchers from the Kimmel Cancer Center (KCC) of Thomas Jefferson University, Philadelphia.
Results of the first open-label study comparing romiplostim treatment with standard- of-care therapies in nonsplenectomized adult patients with chronic immune thrombocytopenia (ITP) show that both the incidence of treatment failure and need for splenectomy were reduced among romiplostim-treated patients.
Minocycline, given before the start of treatment with cetuximab and chemoradiotherapy, plus topical pimecrolimus as needed, can reduce the severity of cetuximab-induced skin toxicity in patients with non–small-cell lung cancer (NSCLC), according to researchers from The Netherlands.
Arsenic trioxide (As2O3) improves survival of patients with acute promyelocytic leukemia (APL) when delivered immediately after induction therapy, according to a new study from researchers with Cancer and Leukemia Group B (Blood. November 11, 2010. Epub ahead of print).
Men treated with long-term androgen deprivation therapy (ADT) for prostate cancer are at increased risk for colorectal cancer, according to a study released in the Journal of the National Cancer Institute.
Denosumab delayed or prevented skeletal-related events (SREs) better than zoledronic acid, according to a study comparing the two agents in patients with breast cancer and bone metastases.
The prognosis for patients with biliary tract cancer is poor, and no standard palliative care has been defined. Now Austrian researchers report that adding cetuximab to gemcitabine and oxaliplatin (GEMOX) for patients with advanced biliary tract cancer results in a high overall response rate and good disease control and is well tolerated.
Age is an important factor when considering tamoxifen therapy for older women with early-stage breast cancer, according to a large retrospective study presented at the 52nd Annual Meeting of the American Society for Radiation Oncology. The findings indicate that older women treated with conservative surgery and radiation therapy (CS + RT) derive only limited benefit from tamoxifen.